Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Motors Company (GM) vs TransMedics Group Inc (TMDX) Price & Performance

General Motors CompanyTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

General Motors Company vs TransMedics Group Inc — how do they compare? General Motors Company trades at $87.27 (market cap $78.40B), while TransMedics Group Inc trades at $86.89 (market cap $3.10B). The key difference: General Motors Company is far larger — about 25.3× TransMedics Group Inc's market cap, and General Motors Company pays a 0.81% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

GMTMDX
Market Cap
$78.40B$3.10B
Sector
Consumer CyclicalTechnology
52-Week High
$90.30$150.42
52-Week Low
$54.16$61.99
Enterprise Value
$181.38B$3.49B
Dividend Yield
0.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Motors Company

General Motors (GM) trades at $87.74, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company has demonstrated consistent earnings outperformance, beating estimates in the last three quarters. Recent strategic moves include a $4.5 billion parts supply deal and extending its China joint venture for 20 years. Valuation metrics show attractive P/S and P/B ratios, though profitability margins remain thin with net income margin at 1.05%.

GM presents a compelling investment case with analyst consensus pointing to 24% upside to the $108.82 price target. Strong cash flow generation and strategic partnerships support growth prospects, but investors face risks from declining profit margins, rising debt levels, and automotive industry cyclicality. The stock's current technical positioning near key support levels suggests potential for near-term stability.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About General Motors Company

General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.

Read more on GM

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX